RPT904: A Study of RAPT904 in People with Food Allergies

A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy RPT904-01

Who can take part?

You may be able to take part if you have a food allergy.

You may be eligible if you:

• Are 12 to 55 years of age
• Have a confirmed allergy to one or more of the following:
• • Peanut
  • Milk
  • Egg
  • Cashew
  • Walnut
• Are able to understand the study and provide consent (parent or guardian consent is required for participants under 18)

You would not be able to take part if:

• You have uncontrolled or severe asthma
• You are pregnant or breastfeeding
• You have a known sensitivity to similar antibody treatments
• You are taking certain medications that may affect the study
• The study doctor feels that participation may not be safe for you

What is involved?

This study is looking at whether a new investigational medication (RAPT904) may help people better tolerate food allergens and reduce allergic reactions.

Participants will be randomly assigned to receive either the study medication or a placebo.

• Study duration: Approximately 68 weeks
• Study periods:
• • Screening (4 weeks)
  • Treatment period 1 (24 weeks)
  • Treatment period 2 (24 weeks)
  • Follow-up (16 weeks)

In the second treatment period, all participants will receive the study medication.

What will I need to do?

If you take part, you will be asked to:

• Attend regular clinic visits and study appointments
• Receive the study medication every 8 to 12 weeks
• Complete questionnaires about your health
• Undergo assessments, which may include:
• • Physical examinations
  • Breathing tests (spirometry)
  • Skin prick testing
  • Blood tests
  • Oral food challenges (under medical supervision)

More information

You can read more about this study here:

• ClinicalTrials.gov – RAPT904 Study